Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicentre study

Further Publications

Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study

Lancet Gastroenterol Hepatol

Lindfors A, Strandberg R, Hagström H

doi: 10.1016/S2468-1253(24)00313-3

Hepatology

Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study

Lancet Gastroenterol Hepatol

Jachs M, Odriozola A, Turon F, Moga L, Téllez L, Fischer P, Saltini D, Kwanten WJ, Grasso M, Llop E, Mendoza YP, Armandi A, Thalhammer J, Pardo C, Colecchia A, Ravaioli F, Maasoumy B, Laleman W, Presa J, Schattenberg JM, Berzigotti A, Calleja JL, Calvaruso V, Francque S, Schepis F, Procopet B, Albillos A, Rautou PE, García-Pagán JC, Puente Á, Fortea JI, Reiberger T, Mandorfer M, SSM-100Hz/ACLD Study Group, Baveno Cooperation

doi: 10.1016/S2468-1253(24)00234-6

Inflammatory Bowel Disease

Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study

Inflamm Bowel Dis

Petrov JC, Desai AA, Kochhar GS, Crosby SK, Kinnucan JA, Picco MF, Hashash JG, Farraye FA

doi: 10.1093/ibd/izae147

Hepatology

Effectiveness of six international guidelines using FIB-4 and FibroScan for risk stratification of MASLD in type 2 diabetes

Clin Gastroenterol Hepatol

Vidal-Trécan T, Julla JB, El Khoury T, Venteclef N, Riveline JP, Paradis V, Valla D, Gautier JF, Castera L

doi: 10.1016/j.cgh.2025.02.018

Gastrointestinal Cancer

Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study

Lancet Gastroenterol Hepatol

Mahajan UM, Oehrle B, Goni E, Strobel O, Kaiser J, Grützmann R, Werner J, Friess H, Gress TM, Seufferlein TW, Uhl W, Will U, Neoptolemos JP, Wittel UA, Vornhülz M, Sirtl S, Beyer G, Regel I, Boeck S, Heinemann V, Frost F, Steveling A, Völzke H, Petersmann A, Nauck M, Weber E, Kamlage B, Lerch MM, Mayerle J, METAPAC trial investigators

doi: 10.1016/S2468-1253(25)00056-1

Hepatology

Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study

Lancet Gastroenterol Hepatol

Lindvig KP, Thorhauge KH, Hansen JK, Kjærgaard M, Hansen CD, Johansen S, Lyngbeck E, Israelsen M, Andersen P, Bech KT, Torp N, Schnefeld HL, Detlefsen S, Möller S, Graupera I, Trelle MB, Antonsen S, Harris R, Kårhus LL, Bjørnsbo KS, Brøns C, Hansen T, Geier A, Wedemeyer H, Zeuzem S, Schattenberg JM, Ginès P, Guha IN, Krag A, Thiele M

doi: 10.1016/S2468-1253(24)00274-7

Hepatology

Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort

J Hepatol

Téllez L, Rincón D, Payancé A, Jaillais A, Lebray P, Rodríguez de Santiago E, Clemente A, Paradis V, Lefort B, Garrido-Lestache E, Prieto R, Iserin L, Tallegas M, Garrido E, Torres M, Muriel A, Perna C, Jesús Del Cerro M, d'Alteroche L, Rautou PE, Bañares R, Albillos A, VALDIG-EASL consortium

doi: 10.1016/j.jhep.2024.09.005

Inflammatory Bowel Disease

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

J Crohns Colitis

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S

doi: 10.1093/ecco-jcc/jjaf080

Gastrointestinal Cancer

Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models

J Gastroenterol Hepatol

Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T, Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

doi: 10.1111/jgh.16871

Related content

Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study

Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study

Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study

Effectiveness of six international guidelines using FIB-4 and FibroScan for risk stratification of MASLD in type 2 diabetes

Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study

Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study

Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models